MGNX Macrogenics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MGNX

Price (delayed)

$3.715

Market cap

$236.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.1

Enterprise value

$274.84M

?
Relative Growth: Rel. Growth: 20
Relative Strength: Rel. Strength: 95
Relative Valuation: Rel. Valuation: 24
Relative Profitability: Rel. Profitability: 24

MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product ...

Highlights
The revenue has increased by 5% QoQ
MGNX's net income is down by 26% YoY but it is up by 6% QoQ
The EPS has contracted by 24% YoY but it has grown by 7% from the previous quarter
MGNX's debt has surged by 181% year-on-year
Macrogenics's equity has shrunk by 73% YoY and by 62% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.macrogenics.com
Peers: XNCR GILD MRK PFE

Key stats

What are the main financial stats of MGNX

MGNX stock price

How has the Macrogenics stock price performed over time
Intraday
0.68%
1 week
-7.13%
1 month
-21.13%
1 year
135.13%
YTD
130.75%
QTD
-19.59%

Financial performance

How have Macrogenics's revenue and profit performed over time
Revenue
$157.08M
Gross profit
$116.94M
Operating income
-$63.66M
Net income
-$70.36M
Gross margin
74.4%
Net margin
-44.8%
Macrogenics's operating margin has increased by 37% YoY and by 17% QoQ
The company's operating income rose by 36% YoY and by 13% QoQ
MGNX's net income is down by 26% YoY but it is up by 6% QoQ
MGNX's net margin is down by 24% year-on-year but it is up by 10% since the previous quarter

Price vs fundamentals

How does MGNX's price correlate with its fundamentals

Growth

What is Macrogenics's growth rate over time

Valuation

What is Macrogenics stock price valuation
P/E
N/A
P/B
11.14
P/S
1.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.75
The EPS has contracted by 24% YoY but it has grown by 7% from the previous quarter
Macrogenics's equity has shrunk by 73% YoY and by 62% QoQ
The price to sales (P/S) is 86% higher than the last 4 quarters average of 0.8 but 68% lower than the 5-year quarterly average of 4.7
The revenue has increased by 5% QoQ

Efficiency

How efficient is Macrogenics business performance
MGNX's return on equity has dropped by 147% year-on-year and by 23% since the previous quarter
MGNX's ROIC has soared by 66% YoY and by 24% QoQ
MGNX's ROA is down by 21% YoY but it is up by 5% from the previous quarter
The ROS has grown by 18% from the previous quarter but it has contracted by 3.1% YoY

Dividends

What is MGNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MGNX.

Financial health

How did Macrogenics financials performed over time
The total assets is 11% more than the total liabilities
The quick ratio has shrunk by 63% QoQ and by 42% YoY
MGNX's current ratio has dropped by 63% since the previous quarter and by 42% year-on-year
MGNX's debt has surged by 181% year-on-year
The debt to equity has surged by 158% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.